Sujaya Srinivasan

TL;DR: Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets.

TL;DR: In this paper, the authors report exploratory analyses of the associations of tumor mutational burden (TMB), a 4-gene inflammatory gene expression signature, and BRAF mutation status with tumor response, progression-free survival, and overall survival in patients with advanced melanoma treated as part of the CheckMate 066 and 067 phase III clinical trials evaluating immuno-oncology therapies.

TL;DR: In-depth evaluation of bioinformatic TMB analysis by whole exome sequencing in formalin-fixed, paraffin-embedded samples from a phase III clinical trial suggests that reliable TMB assessment across assays, platforms, and centers is achievable.

TL;DR: High TMB or high inflammatory signature was associated with benefit to I-O, and higher inflammatory status increased the likelihood of benefit for N+I and N, suggesting further evaluation of these biomarkers to characterize the response toI-O regimens in melanoma.

TL;DR: In-depth evaluation of bioinformatic TMB analysis by whole exome sequencing in formalin-fixed, paraffin-embedded samples from a phase 3 clinical trial shows encouragingly, WES and FoundationOne CDx outputs were highly correlated, suggesting that reliable TMB assessment across assays, platforms, and centers is achievable.